<DOC>
	<DOCNO>NCT02451514</DOCNO>
	<brief_summary>The purpose study evaluate persistence bactericidal antibodies N. meningitidis serogroups A , C , W , Y serogroup B test strain approximately 4 year primary vaccination subject previously receive 2-dose series MenABCWY+Outer membrane Vesicles ( OMV ) single dose MenACWY , evaluate immune response N. meningitidis serogroups A , C , W Y serogroup B test strain 30 day dose MenABCWY+OMV previously vaccinate subject , 30 day 2-dose series vaccine-naive subject similar age , evaluate kinetics immune response 3 , 7 , 30 day booster dose MenABCWY+OMV previously vaccinate subject explore difference kinetics immune response 3 , 7 30 day accelerate 2 dose series MenABCWY+OMV separate 30 day give vaccine-naive subject , assess immunogenicity 2 dos MenABCWY+OMV Day 61 vaccine-naive subject subject previously receive one dose MenACWY</brief_summary>
	<brief_title>A Study Evaluate 4-year Antibody Persistence Booster Response Following MenABCWY Vaccination Healthy Adolescents Young Adults Who Previously Participated Studies V102_02 ( NCT01210885 ) V102_02E1 ( NCT01367158 )</brief_title>
	<detailed_description>Subjects randomise two different blood draw schedule accord 1:1 ratio</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>1 . Individuals receive either 2 dos MenABCWY+OMV single dose MenACWY follow dose placebo , last study vaccine give approximately 48 56 month study V102_02E2 ( NCT01367158 ) , receive Tdap V102_02E1 ( NCT01367158 ) study receive meningococcal vaccine ; Or A proportional number subject site age 15 23 year day inform consent/assent participate V102_02 ( NCT01210885 ) study previously receive meningococcal vaccine . 2 . Individuals / whose parent ( ) /legal guardian ( ) voluntarily give write informed consent/assent nature study explain accord local regulatory requirement , prior study entry . 3 . Individuals comply study procedure include blood draw followup . 4 . Males Or Females nonchildbearing potential Or Females childbearing potential pregnant breastfeed use effective birth control method use least 30 day prior study entry , intend use least 30 day last study vaccination 1 . History meningococcal vaccine administration ( study group C ) History meningococcal vaccine administration vaccination give parent V102_02 ( NCT01210885 ) study ( study group A B ) . 2 . Progressive , unstable uncontrolled clinical condition . 3 . Hypersensitivity , include allergy , component vaccine ( include diphtheria toxoid ( CRM197 ) latex ) whose use foreseen study . 4 . Clinical condition represent contraindication intramuscular vaccination blood draw . 5 . Abnormal function immune system result : a.Clinical condition . 6 . Systemic administration corticosteroid ( PO/IV/IM ) 14 consecutive day within 90 day prior enrollment . 7 . Administration antineoplastic immunomodulating agent radiotherapy within 90 day prior informed consent . 8 . Received immunoglobulin blood product within 90 day prior enrollment . 9 . Received investigational nonregistered medicinal product within 30 day prior enrollment . 10 . Received vaccine within 14 day ( inactivated vaccine ) 28 day ( live vaccine ) prior enrolment study plan receive vaccine within 14 day study vaccine . 11 . Study personnel immediate family household member . 12. Who experience moderate severe acute infection and/or fever ( defined temperature 38Â°C ) within 3 day prior enrollment . 13. Who receive systemic antibiotic treatment within 3 day prior enrollment . 14 . Any clinical condition , opinion investigator , might interfere result study pose additional risk subject due participation study .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>23 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Antibody persistence</keyword>
	<keyword>Young Adults</keyword>
	<keyword>Healthy Adolescents</keyword>
	<keyword>MenABCWY vaccine</keyword>
	<keyword>Booster response</keyword>
	<keyword>MenABCWY+OMV</keyword>
</DOC>